Search

Your search keyword '"Corinne Dot"' showing total 3 results
Start Over Author "Corinne Dot" Publisher hal ccsd
3 results on '"Corinne Dot"'

1. A prospective multicentre study of intravitreal injections and ocular surface in 219 patients: IVIS study

Author

Yannis Badri, Corinne Dot, Pierre Pradat, Yasemin Nakouri, Hussam El Chehab, Laurent Kodjikian, Thibaud Mathis, Roman Chudzinski, Antoine Levron, Frédéric Chiambaretta, Mayeul Chaperon, Sarah Verrecchia, Emilie Agard, Génétique, Reproduction et Développement (GReD), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA), Service d'ophtalmologie [Clermont-Ferrand], CHU Clermont-Ferrand, Matériaux, ingénierie et science [Villeurbanne] (MATEIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Hôpital d'Instruction des Armées Desgenettes, Service de Santé des Armées, and École du Val de Grâce (EVDG)

Subjects
Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Glaucoma, Angiogenesis Inhibitors, Asepsis, [SPI.MAT]Engineering Sciences [physics]/Materials, 03 medical and health sciences, 0302 clinical medicine, Retinal Diseases, Quality of life, Pain assessment, Surveys and Questionnaires, Ophthalmology, medicine, Clinical endpoint, Humans, Ocular Surface Disease Index, Prospective Studies, Aged, Aged, 80 and over, 030203 arthritis & rheumatology, business.industry, Meibomian Glands, Eye drop, General Medicine, Middle Aged, medicine.disease, eye diseases, 3. Good health, Tears, Intravitreal Injections, Quality of Life, 030221 ophthalmology & optometry, Female, business, Conjunctiva, Follow-Up Studies
Abstract

PURPOSE To assess the impact of intravitreal injections (IVTI) on ocular surface of patients treated with multiple injections. METHODS Prospective, tricentric study conducted in patients treated with unilateral IVTI. An asepsis protocol with povidone-iodine was used for all patients during IVTI. The primary endpoint was the difference between the pre-IVTI Ocular Surface Disease Index (OSDI 1) score and that measured on day one (D1) post-IVTI (OSDI 2). Secondary endpoints were the evaluation of predictive factors for OSDI scores, pain assessment on D1, and the Lacrydiag® analysis of tears from the injected eye versus contralateral eye before IVTI. RESULTS Two hundred and nineteen patients with a mean age of 75.9 ± 10 years were included. The mean OSDI2-OSDI1 difference was 19.2 ± 20.6 (p

Published
2021
Full Text
View/download PDF

2. Increased choroidal thickness: a new feature to monitor age-related macular degeneration recurrence

Author

Laurent Kodjikian, Emilie Agard, Philippe Denis, Hussam El-Chehab, Corinne Dot, Zainab Machkour‐Bentaleb, Maud Mendes, Thibaud Mathis, V. Bouteleux, Matériaux, ingénierie et science [Villeurbanne] (MATEIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Hydrosystèmes et Bioprocédés (UR HBAN), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA), and Hydrosystèmes et bioprocédés (UR HBAN)

Subjects
0301 basic medicine, choroidal thickness, Male, Vascular Endothelial Growth Factor A, systolic blood pressure, genetic structures, intervention study, recurrent disease, very elderly, Angiogenesis Inhibitors, mixed age related macular degeneration, [SPI.MAT]Engineering Sciences [physics]/Materials, chemistry.chemical_compound, dry retina, 0302 clinical medicine, Recurrence, 80 and over, Prospective Studies, Fluorescein Angiography, Tomography, Aged, 80 and over, medicine.diagnostic_test, aflibercept, clinical trial, Organ Size, VEGFA protein, Sensory Systems, 3. Good health, medicine.anatomical_structure, spectral domain optical coherence tomography, priority journal, Intravitreal Injections, Female, Tomography, Optical Coherence, retina neovascularization, prospective study, medicine.medical_specialty, diagnostic imaging, age related macular degeneration, subretinal neovascularization, bevacizumab, polypoidal choroidal vasculopathy, Article, 03 medical and health sciences, Cellular and Molecular Neuroscience, Optical coherence tomography, Ophthalmology, Age related, retina disease, choroidal neovascularization type 3, medicine, choroidal neovascularization type 1, follow up, Humans, choroidal neovascularization type 2, human, ranibizumab, antagonists and inhibitors, Aged, Retina, optical coherence tomography, business.industry, Choroid, diastolic blood pressure, reticular pseudodrusen, Retinal, retinal angiomatous proliferation, fluorescence angiography, Macular degeneration, intravitreal drug administration, medicine.disease, major clinical study, eye diseases, clinical feature, 030104 developmental biology, Blood pressure, angiogenesis inhibitor, multicenter study, chemistry, vasculotropin A, Optical Coherence, 030221 ophthalmology & optometry, Wet Macular Degeneration, pathology, Enhanced depth imaging, sense organs, business, Follow-Up Studies
Abstract

cited By 0; Purpose: The main objective of this study was to assess choroidal thickness (CT) changes during an exudative recurrence of age-related macular degeneration (AMD). Methods: A real-life prospective non-interventional 9-month study was conducted in two centers in consecutive patients with exudative AMD between November 2016 and July 2017. CT was measured manually in both eyes based on enhanced-depth imaging spectral-domain optical coherence tomography at different follow-up visits scheduled in the morning. Results: A total of 134 patients were included. Ninety-five patients presented at least one episode, defined by a follow-up visit under controlled condition (dry retina) followed by a visit for exudative recurrence. A total of 119 episodes were analyzed. The mean CT change in the treated eye was + 8.45 ± 13.52 μm (p < 0.001) and + 5.62 ± 14.77 μm (p = 0.009) respectively in the subfoveal area and nasal area. No significant change in CT was observed in the fellow eye. No significant association between CT changes and treatment, number of intravitreal injections, and blood pressure was observed. Conclusion: CT increased in case of exudative recurrence of neovascular AMD. The increase was mild but significant. Thus, CT could be used as a monitoring criterion, like the central retinal thickness, in AMD management. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.

Published
2019
Full Text
View/download PDF

3. Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine-Gass syndrome: the EPISODIC-2 study

Author

Claire Scemama, Carole Burillon, Stéphanie Baillif, Frédéric Matonti, David Bellocq, Jad Akesbi, Vincent Soler, Vincent Pierre-Kahn, Corinne Dot, Laurent Kodjikian, Benjamin Wolff, Solange Milazzo, Michel Weber, Nicolas Voirin, Ariane Malclès, CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Ophtalmologie [Hôpital de la Timone - APMH], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Neurosciences de la Timone (INT), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Biologie Tissulaire et d'ingénierie Thérapeutique UMR 5305 (LBTI), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Hôpital l'Archet, Fondation Ophtalmologique Adolphe de Rothschild, Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital de la Croix-Rousse [CHU - HCL], Matériaux, ingénierie et science [Villeurbanne] (MATEIS), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [APHP], Aix Marseille Université ( AMU ) -Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Institut de Neurosciences de la Timone ( INT ), Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de Biologie Tissulaire et d'ingénierie Thérapeutique UMR 5305 ( LBTI ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ), Hospices Civils de Lyon ( HCL ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Universitaire de Nantes, Matériaux, ingénierie et science [Villeurbanne] ( MATEIS ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ) -Institut National des Sciences Appliquées de Lyon ( INSA Lyon ), Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Institut National des Sciences Appliquées ( INSA ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Fondation Ophtalmologique Adolphe de Rothschild [Paris]

Subjects
Male, 0301 basic medicine, Intraocular pressure, Visual acuity, genetic structures, Visual Acuity, Macular oedema, Dexamethasone, [SPI.MAT]Engineering Sciences [physics]/Materials, Postoperative Complications, 0302 clinical medicine, Aged, 80 and over, Drug Implants, Macula, Drugs, Diabetic retinopathy, Middle Aged, Sensory Systems, 3. Good health, Intravitreal Injections, Female, medicine.symptom, medicine.drug, Adult, medicine.medical_specialty, [ SPI.MAT ] Engineering Sciences [physics]/Materials, Macular Edema, Young Adult, 03 medical and health sciences, Cellular and Molecular Neuroscience, Refractory, Ophthalmology, medicine, Humans, Irvine-Gass syndrome, Glucocorticoids, Aged, Retrospective Studies, Inflammation, business.industry, medicine.disease, eye diseases, Surgery, ddc:616.8, 030104 developmental biology, Delayed-Action Preparations, 030221 ophthalmology & optometry, Implant, business
Abstract

Aim To assess the effectiveness and safety of intravitreal dexamethasone implants for treating post-surgical macular oedema, including Irvine-Gass syndrome refractory to first-line treatments. Methods Descriptive, observational, retrospective, consecutive, uncontrolled, multicentre, national case series. 50 patients were included in the study between March 2011 and June 2013 with a minimum 6 months follow-up. At baseline, each patient received a dexamethasone implant 0.7 mg (Ozurdex). Best-corrected visual acuity (BCVA), central subfield macular thickness (CSMT), and intraocular pressure (IOP) were measured at baseline and then monthly. The main outcome measure was the mean change in BCVA (in ETDRS letters (Early Treatment Diabetic Retinopathy Study): L) Results Baseline mean±SD BCVA was 55.7±15.4 L. At month 2, BCVA was 71.8±10.5 L and 61.2% of patients had an increase of more than 15 letters. Baseline mean CSMT was 544±117.2 μm and this decreased to 302 μm at month 2. Anatomic and functional recurrences were both first detected from month 3 and continued throughout follow-up, with values consistently above baseline. The peak in IOP was reached in month 1 with mean IOP of 15.3±4.6 mm Hg. Of the 39/50 patients followed up for 12 months, 49% received a second injection. The anatomic and functional response and safety patterns were similar to that obtained with the first intravitreal injection, demonstrating Ozurdex’s reproducibility. However, more than half of the patients followed-up for at least 1 year presented neither functional nor anatomical recurrence. Conclusions Ozurdex would appear to be an interesting alternative therapy for treating post-surgical macular oedema, including Irvine-Gass syndrome refractory to first-line treatments.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results